# Page 96 Audit — Chapter 5: Rec 5.2.1 Costs, Rationale, Figure 34 Chronic Care Model

## Page Identity
- **PDF page**: S95 (Chapter 5 — www.kidney-international.org)
- **Content**: Rec 5.2.1 continuation — resource use/costs (50% reduced CV risk, cost-effective/saving), implementation considerations, rationale (8-fold mortality risk, care gaps), Figure 34 (chronic care model)
- **Clinical tier**: T3 (Informational — evidence outcomes, implementation, care model)
- **Job ID**: df538e50-0170-4ef8-862d-5b0a7c48e4ff
- **Disagreement flag**: YES
- **Prior review**: 1/7 spans already CONFIRMED by a previous reviewer

## Extraction Summary
| Metric | Value |
|--------|-------|
| Total spans | 7 |
| T1 (Patient Safety) | 2 |
| T2 (Clinical Accuracy) | 5 |
| T3 (Informational) | 0 |
| Channels present | C (Grammar/Regex), F (NuExtract LLM), B (Drug Dictionary) |
| Genuinely correct T1 | 0 |
| Genuinely correct T2 | 0 |
| Tier accuracy | 0% (0/7) |
| Disagreements | 1 |
| Review Status | FINAL: 14 ADDED, 1 CONFIRMED, 6 REJECTED |
| Audit Date | 2026-02-25 (revised) |
| Cross-Check | 2026-02-25 — counts confirmed (7 total: 2 T1, 5 T2), channels confirmed (B, C, F) |
| Raw PDF Cross-Check | 2026-02-28 — 1 agent span kept (CONFIRMED), 6 rejected, 14 gaps added (G96-A–G96-N) |

## Channel Breakdown
| Channel | Count | Confidence | Content |
|---------|-------|------------|---------|
| F (NuExtract LLM) | 3 | 85% | Implementation prose + RCT evidence + barriers prose |
| C (Grammar/Regex) | 2 | 85% | "HbA1c" + "daily" bare terms |
| B (Drug Dictionary) | 2 | 100% | "statins" + "RASi" drug class names |

## T1 Spans (2) — BOTH MISTIERED

| # | Text | Channel | Conf | Status | Correct Tier | Issue |
|---|------|---------|------|--------|-------------|-------|
| 1 | "This recommendation recognizes potential resource constraints and insufficient capacity in delivering team-based care, e..." | F | 85% | PENDING | T3 | Implementation consideration prose — not patient safety content |
| 2 | "statins" | B | 100% | PENDING | T3 | Drug class name in evidence context ("use of RASi and statins have been shown to reduce...") |

**Analysis**:
- Span #1: F channel extracted a sentence about resource constraints as T1. This is about healthcare system capacity, not patient safety.
- Span #2: B channel's standard drug name extraction. "statins" appears in the rationale paragraph stating that statins reduce cardiovascular-kidney disease risk — informational context, not a prescribing directive.

## T2 Spans (5) — ALL MISTIERED

| # | Text | Channel | Conf | Status | Correct Tier | Issue |
|---|------|---------|------|--------|-------------|-------|
| 1 | "HbA1c" | C | 85% | PENDING | T3 | Bare lab name in evidence context |
| 2 | "daily" | C | 85% | PENDING | NOISE | Bare temporal word without context |
| 3 | "Both of these team-based care models in patients with T2D and CKD focusing on treatment with multiple targets and self-m..." | F | 85% | **CONFIRMED** | T3 | Cost-effectiveness evidence summary — already reviewed |
| 4 | "In high-income countries, system and financial barriers often make delivery of quality diabetes/kidney care suboptimal, ..." | F | 85% | PENDING | T3 | Health system barriers prose |
| 5 | "RASi" | B | 100% | PENDING | T3 | Drug class abbreviation in evidence context |

### Previously Reviewed Span
Span #3 (F 85%) was already CONFIRMED by a prior reviewer. This is the first reviewed span encountered in Chapter 5. The span describes cost-effectiveness of team-based care models — correctly T3 informational, but confirmed as T2 by the reviewer. This highlights the tier confusion even among human reviewers.

## PDF Source Content Analysis

### Content Present on Page
1. **Resource use and costs** (continuation from page 95):
   - 7.8-year RCT: Team-based multifactorial care → **50% reduced risk of CV events** vs usual care
   - Translated to reduced hospitalization + **gain of 7.9 years of life** after 20 years
   - Both team-based models **cost-effective and cost-saving** in primary care setting

2. **Implementation considerations**:
   - Resource constraints acknowledged, especially in low/middle-income countries
   - "Train the trainer" approach for prevention
   - High-income country barriers: system and financial barriers
   - Need to build capacity, strengthen system, reward preventive care

3. **Rationale**:
   - Diabetes+CKD → **8-fold higher risk** of cardiovascular and all-cause mortality
   - Control of blood glucose, blood pressure, cholesterol + RASi + statins reduces CV-kidney risk
   - Considerable care gaps in low-, middle-, and high-income countries
   - Chronic care model: care organization + informed patients + proactive care teams
   - Protocol-driven care analogy to clinical trials

4. **Figure 34**: Chronic care model schematic:
   - Community resources and policies
   - Self-management support
   - CKD health systems / Organization of CKD care
   - Delivery system design
   - Decision support
   - Clinical information systems
   - Informed activated patient ↔ Prepared proactive multidisciplinary team → Productive interactions → Improved outcomes

### What Should Have Been Extracted
| Content | Correct Tier | Extracted? |
|---------|-------------|------------|
| "50% reduced risk of cardiovascular events" | T3 | NO (specific outcome magnitude) |
| "gain of 7.9 years of life after 20 years" | T3 | NO (specific outcome) |
| "8-fold higher risk of cardiovascular and all-cause mortality" | T3 | NO (risk multiplier) |
| "cost-effective and cost-saving" conclusion | T3 | YES (span #3, mistiered as T2) |
| "use of RASi and statins" reduces CV-kidney risk | T3 | Partially — drug names extracted separately without clinical context |
| Figure 34 chronic care model components | T3 | NO |

## Cross-Page Patterns

### B Channel Drug Names in Rationale Sections
"statins" and "RASi" are mentioned in the rationale paragraph: "Control of blood glucose, blood pressure, and blood cholesterol, as well as the use of RASi and statins, have been shown to reduce the risk of cardiovascular-kidney disease." B channel extracted both drug class names but without the clinical context that gives them meaning.

### No HTML Artifact on This Page
Unlike pages 91-95, page 96 does NOT have a `<!-- PAGE 96 -->` F channel artifact. This may mean the F channel had enough meaningful content to extract that the HTML comment was pushed out of the extraction window, or the artifact pattern is intermittent.

### C Channel Bare Terms Continue
"HbA1c" and "daily" are the same C channel noise pattern seen throughout: bare lab names and temporal words extracted without clinical context.

## Quality Assessment

| Dimension | Rating | Notes |
|-----------|--------|-------|
| Extraction completeness | LOW | Key outcome magnitudes (50% risk reduction, 8-fold mortality, 7.9 years) all missed |
| Tier accuracy | 0% | 2 T1 should be T3, 5 T2 should be T3/NOISE |
| Clinical safety risk | NONE | Evidence review, implementation guidance, and care model |
| Channel diversity | MODERATE | B + C + F (3 channels) |
| Noise level | HIGH | Drug names and bare terms without context |
| Prior review status | 1/7 CONFIRMED | One span previously reviewed |

## Decision Recommendation
**ACCEPT** — Zero clinical safety risk. All content is evidence review, implementation guidance, and care model rationale. The 1 previously confirmed span doesn't change the assessment.

---

## Raw PDF Cross-Check (2026-02-28)

### Pre-Review State
- **Total spans**: 7
- **ADDED**: 4 (from agent bulk audit: 50% CV risk reduction, 7.9 years life gain, 8-fold mortality risk, blood glucose/BP/cholesterol+RASi/statins)
- **CONFIRMED**: 1 (`adcce75b` — cost-effective team-based care, from prior reviewer)
- **PENDING**: 0
- **REJECTED**: 6 (resource constraints prose, drug names, bare lab terms, implementation barriers)

### Agent Spans Kept (5)
| # | ID | Status | Text (truncated) | Note |
|---|-----|--------|----------|------|
| G96-A | `9f315332` | ADDED | 50% reduced risk of cardiovascular events | CV risk reduction |
| G96-B | `9cdb1e15` | ADDED | gain of 7.9 years of life after 20 years | Life-years gained |
| G96-C | `27841c6b` | ADDED | 8-fold higher risk of cardiovascular and all-cause mortality | Mortality risk multiplier |
| G96-D | `346bc2c5` | ADDED | Control of blood glucose, blood pressure, and blood cholesterol, as well as the use of RASi and statins... | Risk factor control + therapy |
| — | `adcce75b` | CONFIRMED | Both of these team-based care models in patients with T2D and CKD... cost-effective and cost-saving... | Cost-effectiveness (prior reviewer) |

### Gaps Added (10) — Exact PDF Text

| # | ID | Gap Text (truncated) | Note |
|---|-----|----------|------|
| G96-E | — | increased albuminuria who received team-based multifactorial care had a 50% reduced risk of cardiovascular events... reduced hospitalization rates and a gain of 7.9 years of life after 20 years. | Full RCT context for CV reduction + life-years |
| G96-F | — | This recommendation recognizes potential resource constraints... low-income and middle-income countries... "train the trainer" approach... prevent onset and progression of complications such as CKD. | Implementation — LMICs, train-the-trainer |
| G96-G | — | In high-income countries, system and financial barriers often make delivery of quality diabetes/kidney care suboptimal... build capacity, strengthen the system, and reward preventive care... | Implementation — HIC barriers |
| G96-H | — | in real-world practice, there are considerable care gaps in low-income, middle-income, and high-income countries... lack of timely and personalized information... | Care gaps — information deficit |
| G96-I | — | Although self-care represents a cornerstone of diabetes management... need to take cultures, preferences, and values into consideration... individualize diabetes education... | Self-care + cultural adaptation |
| G96-J | — | Care organization, informed patients, and proactive care teams form the pillars of the chronic care model aimed at promoting self-management and shared decision-making. | Chronic care model pillars |
| G96-K | — | Figure 34 \| The chronic care model... additive benefits of different components at the system, policy, provider, and patient levels... Epping-Jordan JE, Pruitt SD, Bengoa R, et al., 2004 | Figure 34 caption + source |
| G96-L | — | Community Resources and policies. Self-management support. CKD health systems: Organization of CKD care. Delivery system design. Clinical information systems. Decision support... | Figure 34 components |
| G96-M | — | The concept of a chronic care model... analogous to the protocol-driven care in clinical trial settings... trial participants often had considerably lower event rates than their peers... | Structured care vs real-world gap |
| G96-N | — | despite the relative lack of direct evidence, the Work Group judged that multidisciplinary integrated care for patients with diabetes and CKD would represent a good investment for health systems... | Work Group investment judgment |

### Post-Review State
- **Total spans**: 21
- **ADDED**: 14 (4 from bulk audit + 10 new gaps)
- **CONFIRMED**: 1 (prior reviewer)
- **REJECTED**: 6 (agent noise)
- **P2-ready facts**: 15

### KB Routing
| Gap | Target KB | Rationale |
|-----|-----------|-----------|
| G96-A–C, G96-E | KB-16 (Monitoring) | Outcome magnitudes: 50% CV reduction, 7.9 years, 8-fold mortality |
| G96-D | KB-1 (Dosing) | RASi + statins for CV-kidney risk reduction |
| G96-F, G96-G | KB-4 (Safety) | Implementation considerations for LMICs and HICs |
| G96-H, G96-I | KB-4 (Safety) | Care gaps, self-care, cultural adaptation |
| G96-J–G96-L | KB-4 (Safety) | Chronic care model (Figure 34) pillars + components |
| G96-M, G96-N | KB-4 (Safety) | Structured care rationale, Work Group judgment |

## Audit Metadata
- **Audited**: 2026-02-24
- **Method**: Playwright browser UI (Phase 2B Page Browse)
- **Auditor**: Claude (automated)
- **Raw PDF Cross-Check**: 2026-02-28 (claude-auditor via API)
- **Page in sequence**: 96 of 126
